P Bytzer

Summary

Affiliation: University of Copenhagen
Country: Denmark

Publications

  1. ncbi Cost-effectiveness of gastroscopy
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Denmark
    Ital J Gastroenterol Hepatol 31:749-60. 1999
  2. ncbi Treatment of Helicobacter pylori
    Peter Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Helicobacter 10:40-6. 2005
  3. ncbi [Nobel Prize for the discovery of Helicobacter pylori. The Danish Society of Gastroenterology]
    Peter Bytzer
    Medicinsk Gastroenterologisk Afdeling M1, Amtssygehuset i Glostrup, DK-2600 Glostrup
    Ugeskr Laeger 168:1216. 2006
  4. ncbi Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial
    Peter Bytzer
    Køge University Hospital and Copenhagen University, Copenhagen, Denmark
    Clin Gastroenterol Hepatol 11:246-52.e1-5. 2013
  5. ncbi Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study
    Peter Bytzer
    Department of Gastroenterology, Køge University Hospital, Copenhagen University, Lykkebækvej 1, 4600 Køge, Denmark
    Am J Cardiovasc Drugs 13:27-35. 2013
  6. ncbi Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease
    Peter Bytzer
    Department of Medicine, Køge University Hospital, Køge, Denmark
    Clin Gastroenterol Hepatol 10:1360-6. 2012
  7. ncbi Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients
    P Bytzer
    Department of Medical Gastroenterology, Køge University Hospital, University of Copenhagen, Denmark
    Aliment Pharmacol Ther 36:635-43. 2012
  8. ncbi Work productivity improvement after acid suppression in patients with uninvestigated dyspepsia
    Peter Bytzer
    Medicinsk afdeling, Køge Sygehus, Lykkebækvej 1, Køge, Denmark
    Dan Med J 59:A4461. 2012
  9. ncbi Impact of an information video before colonoscopy on patient satisfaction and anxiety - a randomized trial
    P Bytzer
    Department of Gastroenterology, Glostrup University Hospital, Copenhagen, Denmark
    Endoscopy 39:710-4. 2007
  10. ncbi Dyspepsia as an adverse effect of drugs
    Peter Bytzer
    Department of Gastroenterology, Køge University Hospital, Copenhagen University, DK 4600 Køge, Denmark
    Best Pract Res Clin Gastroenterol 24:109-20. 2010

Detail Information

Publications63

  1. ncbi Cost-effectiveness of gastroscopy
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Denmark
    Ital J Gastroenterol Hepatol 31:749-60. 1999
    ..In view of the rapidly changing epidemiology of Helicobacter pylori infection in the Western world the long-term effects of such a policy should be monitored closely...
  2. ncbi Treatment of Helicobacter pylori
    Peter Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Helicobacter 10:40-6. 2005
    ..Novel agents have been tried, but with disappointing results. New drugs and administration forms have been reported but their efficacy needs confirmation...
  3. ncbi [Nobel Prize for the discovery of Helicobacter pylori. The Danish Society of Gastroenterology]
    Peter Bytzer
    Medicinsk Gastroenterologisk Afdeling M1, Amtssygehuset i Glostrup, DK-2600 Glostrup
    Ugeskr Laeger 168:1216. 2006
  4. ncbi Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial
    Peter Bytzer
    Køge University Hospital and Copenhagen University, Copenhagen, Denmark
    Clin Gastroenterol Hepatol 11:246-52.e1-5. 2013
    ..We analyzed data from this trial to quantify upper gastrointestinal nonbleeding adverse events (NB-UGI AEs)...
  5. ncbi Burden of upper gastrointestinal symptoms in patients receiving low-dose acetylsalicylic acid for cardiovascular risk management: a prospective observational study
    Peter Bytzer
    Department of Gastroenterology, Køge University Hospital, Copenhagen University, Lykkebækvej 1, 4600 Køge, Denmark
    Am J Cardiovasc Drugs 13:27-35. 2013
    ..It is well established, however, that troublesome upper gastrointestinal (GI) symptoms are commonly experienced among low-dose ASA users...
  6. ncbi Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease
    Peter Bytzer
    Department of Medicine, Køge University Hospital, Køge, Denmark
    Clin Gastroenterol Hepatol 10:1360-6. 2012
    ..We evaluated the diagnostic performance of the PPI test, in conjunction with other tests, for the diagnosis of GERD...
  7. ncbi Partial symptom-response to proton pump inhibitors in patients with non-erosive reflux disease or reflux oesophagitis - a post hoc analysis of 5796 patients
    P Bytzer
    Department of Medical Gastroenterology, Køge University Hospital, University of Copenhagen, Denmark
    Aliment Pharmacol Ther 36:635-43. 2012
    ..Although most patients with gastro-oesophageal reflux disease (GERD) benefit from proton pump inhibitor (PPI) therapy, some experience only partial symptom relief...
  8. ncbi Work productivity improvement after acid suppression in patients with uninvestigated dyspepsia
    Peter Bytzer
    Medicinsk afdeling, Køge Sygehus, Lykkebækvej 1, Køge, Denmark
    Dan Med J 59:A4461. 2012
    ..Lost productivity accounts for a significant part of the costs caused by gastrointestinal symptoms. We aimed to describe selfreported productivity in patients presenting with dyspepsia...
  9. ncbi Impact of an information video before colonoscopy on patient satisfaction and anxiety - a randomized trial
    P Bytzer
    Department of Gastroenterology, Glostrup University Hospital, Copenhagen, Denmark
    Endoscopy 39:710-4. 2007
    ..Anxiety before colonoscopy may have adverse consequences and increase requirements for sedation and analgesics. We aimed to examine the effects of adding an information video to our usual preprocedural information...
  10. ncbi Dyspepsia as an adverse effect of drugs
    Peter Bytzer
    Department of Gastroenterology, Køge University Hospital, Copenhagen University, DK 4600 Køge, Denmark
    Best Pract Res Clin Gastroenterol 24:109-20. 2010
    ..The mechanisms by which a drug causes dyspepsia are often unknown even though some drugs are known to cause direct mucosal injury. Non-steroidal anti-inflammatory drugs and antibiotics are common causes of drug-related dyspepsia...
  11. ncbi Assessment of reflux symptom severity: methodological options and their attributes
    P Bytzer
    Department of Medicine, Division of Gastroenterology, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Gut 53:iv28-34. 2004
    ..Here, the available data on the assessment of reflux symptoms--predominantly heartburn--in clinical trials of symptomatic reflux disease are examined...
  12. ncbi Six-month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Denmark
    Aliment Pharmacol Ther 20:181-8. 2004
    ..Compliance studies have shown that patients with reflux symptoms generally take their medication only when experiencing these symptoms...
  13. ncbi Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment
    Peter Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Scand J Gastroenterol 41:1132-40. 2006
    ..g. acid regurgitation, epigastric pain, dysphagia), effect on quality of life, patient satisfaction with treatment, and adverse events...
  14. ncbi Diagnostic approach to dyspepsia
    Peter Bytzer
    Department of Medical Gastroenterology and Endoscopy, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Best Pract Res Clin Gastroenterol 18:681-93. 2004
    ..In the near future, the empirical acid inhibition strategy will probably be cost-effective as gastro-oesophageal reflux becomes the predominant disorder in dyspeptic patients...
  15. ncbi [Acid-related disorders]
    Peter Bytzer
    Køge Sygehus, Medicinsk afdeling, Gastroenterologisk Sektion, Køge
    Ugeskr Laeger 170:525-7. 2008
    ..A symptom-driven management approach will reduce long term drug intake in reflux patients. The proportion of H. pylori-negative ulcers has increased; helicobacter status must be assessed in all ulcer patients...
  16. ncbi Personal view: rationale and proposed algorithms for symptom-based proton pump inhibitor therapy for gastro-oesophageal reflux disease
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Aliment Pharmacol Ther 20:389-98. 2004
    ..These algorithms must specify the initial evaluation and treatment of candidates, and follow-up protocols for an on-demand strategy. Our group has developed such algorithms, which are presented here...
  17. ncbi H(2) receptor antagonists and prokinetics in dyspepsia: a critical review
    Peter Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Gut 50:iv58-62. 2002
    ..Evaluating the therapeutic gain of cisapride is more difficult but meta-analyses indicate a somewhat larger effect...
  18. ncbi Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Aliment Pharmacol Ther 14:1479-84. 2000
    ..Most patients with dyspeptic symptoms are treated empirically. Drug-induced dyspepsia might therefore be reflected in the sequencing of prokinetics relative to other medications...
  19. ncbi On-demand therapy for gastro-oesophageal reflux disease
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Copenhagen, Denmark
    Eur J Gastroenterol Hepatol 13:S19-22. 2001
    ..First-dose acid suppression and symptom relief vary among PPIs; these differences require further investigation...
  20. ncbi Identifying responders to acid suppression in dyspepsia using a random starting day trial
    P Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Denmark
    Aliment Pharmacol Ther 14:1485-94. 2000
    ..This may be the reason for the general failure of acid suppression in clinical trials in these patients. It may be more rewarding to identify true responders to drug treatment by a single subject trial...
  21. ncbi Oral hypoglycaemic drugs and gastrointestinal symptoms in diabetes mellitus
    P Bytzer
    Department of Medicine, University of Sydney, Nepean Hospital, Sydney, Australia
    Aliment Pharmacol Ther 15:137-42. 2001
    ..Gastrointestinal symptoms in diabetic patients have also been linked to factors associated with long-standing disease and suboptimal control...
  22. ncbi A population-based survey to assess troublesome symptoms in gastroesophageal reflux disease
    Christina Reimer
    Department of Medical Gastroenterology, Køge University Hospital, Denmark
    Scand J Gastroenterol 44:394-400. 2009
    ..The objectives of this study were to examine the characteristics for troublesome symptoms and to compare different ways of categorizing reflux symptoms as troublesome...
  23. ncbi Impact of chronic gastrointestinal symptoms in diabetes mellitus on health-related quality of life
    N J Talley
    Department of Medicine, University of Sydney, Nepean Hospital, Kingswood, New South Wales, Australia
    Am J Gastroenterol 96:71-6. 2001
    ..0001) associated with poorer quality of life in diabetes, independent of age, gender, smoking, alcohol use, and type of diabetes. CONCLUSIONS: GI symptoms impact negatively on health-related quality of life in diabetes mellitus...
  24. ncbi Low socioeconomic class is a risk factor for upper and lower gastrointestinal symptoms: a population based study in 15 000 Australian adults
    P Bytzer
    Department of Medicine, University of Sydney, Nepean Hospital, Penrith, Australia
    Gut 49:66-72. 2001
    ..Low socioeconomic class should be considered a risk factor for both upper and lower gastrointestinal symptoms...
  25. ncbi Identifying response to acid suppressive therapy in functional dyspepsia using a random starting day trial--is gastro-oesophageal reflux important?
    L G Madsen
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Aliment Pharmacol Ther 20:423-30. 2004
    ..Single subject trials offer an alternative approach to identify and characterize responders to a specific treatment...
  26. ncbi Prevalence of gastrointestinal symptoms associated with diabetes mellitus: a population-based survey of 15,000 adults
    P Bytzer
    Department of Medicine, University of Sydney, Nepean Hospital, Clinical Sciences Building, PO Box 63, Penrith, New South Wales 2751, Australia
    Arch Intern Med 161:1989-96. 2001
    ..CONCLUSIONS: Diabetes mellitus is associated with an increased prevalence of upper and lower gastrointestinal symptoms. This effect may be linked to poor glycemic control but not to duration of diabetes or type of treatment...
  27. ncbi Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis--results from a randomized trial with 2-year follow-up
    P Bytzer
    Department of Medicine M, Glostrup University Hospital, Denmark
    Am J Gastroenterol 96:1409-16. 2001
    ..pylori-negative patients, especially if treated empirically with eradication therapy. These results suggest that H. pylori infection should be assessed in all duodenal ulcer patients before treatment is decided...
  28. ncbi [Prevention of NSAID induced gastroduodenal ulcers]
    J M Hansen
    Medicinsk Afdeling M, Gastroenterologisk Sektion, Amtssygehuset i Glostrup
    Ugeskr Laeger 163:6103-5. 2001
    ..Lower doses of misoprostol are less effective and are still associated with diarrhea. Only misoprostol 800 micrograms/day has been directly shown to reduce the risk of ulcer complications...
  29. ncbi Psychological distress is linked to gastrointestinal symptoms in diabetes mellitus
    S J Talley
    Department of Medicine, University of Sydney, Nepean Hospital, NSW, Australia
    Am J Gastroenterol 96:1033-8. 2001
    ..It is uncertain whether psychological distress is causally linked to symptoms, or whether GI symptoms per se increase levels of anxiety and depression...
  30. ncbi The validity of a symptom diary in ratings of dyspepsia measured against a detailed interview: do patients and clinicians agree in their assessment of symptoms?
    L G Madsen
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Aliment Pharmacol Ther 26:905-12. 2007
    ..Patients' self-assessment of symptoms is central in drug treatment trials of functional dyspepsia. The validity of such ratings is important...
  31. ncbi Current indications for acid suppressants in dyspepsia
    P Bytzer
    Department of Medicine, Division of Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Best Pract Res Clin Gastroenterol 15:385-400. 2001
    ..In conclusion, there appears to be a subgroup of patients with functional dyspepsia who will respond to acid suppression over and above placebo, but further work is required to characterize these responders...
  32. ncbi [Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients]
    Bo Søndergaard
    Medicinsk Gastroenterologisk Afdeling M1, Amtssygehuset i Glostrup
    Ugeskr Laeger 167:500-2. 2005
  33. ncbi Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy
    Christina Reimer
    Department of Medical Gastroenterology, Køge University Hospital, Copenhagen University, Copenhagen, Denmark
    Gastroenterology 137:80-7, 87.e1. 2009
    ..Rebound acid hypersecretion (RAHS) has been demonstrated after 8 weeks of treatment with a proton-pump inhibitor (PPI). If RAHS induces acid-related symptoms, this might lead to PPI dependency and thus have important implications...
  34. ncbi Prescribing of acid suppressive therapy: interactions between hospital and primary care
    A Krag
    Department of Medicine, Svendborg Hospital, Svendborg, Denmark
    Aliment Pharmacol Ther 23:1713-8. 2006
    ..8% were seen in our department. CONCLUSIONS: Decisions about acid suppressive therapy prescribing in hospital has little influence on prescribing in primary care...
  35. ncbi Randomised clinical trial: identification of responders to short-term treatment with esomeprazole for dyspepsia in primary care - a randomised, placebo-controlled study
    V Meineche-Schmidt
    Department of General Practice, The Panum Institute, University of Copenhagen, Denmark
    Aliment Pharmacol Ther 33:41-9. 2011
    ..Response to proton pump inhibitor (PPI) treatment in dyspepsia is unpredictable...
  36. ncbi Dyspepsia
    P Bytzer
    Department of Medicine M, Division of Gastroenterology, Glostrup University Hospital, DK-2600 Glostrup, Denmark
    Ann Intern Med 134:815-22. 2001
    ..Further testing and validation are in progress...
  37. ncbi Symptomatic response to blocked and unblocked pentagastrin stimulation in functional dyspepsia. Comparison of responders and non-responders to omeprazole identified in a single-subject trial model
    Lone Galmstrup Madsen
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Dig Dis 26:237-42. 2008
    ..In non-responders, epigastric pain was expected not to be influenced by gastric acid stimulation or type of treatment...
  38. ncbi Goals of therapy and guidelines for treatment success in symptomatic gastroesophageal reflux disease patients
    Peter Bytzer
    Department of Medicine, Division of Gastroenterology, Glostrup University Hospital, DK-2600 Glostrup, Denmark
    Am J Gastroenterol 98:S31-9. 2003
    ..However, the prevention of erosive esophageal damage, strictures, and adenocarcinoma should be a goal of long-term treatment success, even in symptomatic GERD...
  39. ncbi The Rome II and Rome III criteria identify the same subtype-populations in irritable bowel syndrome: agreement depends on the method used for symptom report
    A L Engsbro
    Department of Medicine, Køge University Hospital, University of Copenhagen, Denmark
    Neurogastroenterol Motil 24:604-11, e266. 2012
    ..Our aim was to determine the agreement between Rome II and Rome III subtypes, and to explore whether agreement depends on the symptom reporting method...
  40. ncbi Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification
    A L Engsbro
    Department of Medicine, Køge Hospital, University of Copenhagen, Denmark
    Aliment Pharmacol Ther 35:350-9. 2012
    ..In irritable bowel syndrome (IBS) subtyping is used in research and clinical practice. Knowledge of subtype stability is needed for proper design of trials and treatment strategies...
  41. ncbi Helicobacter pylori test-and-eradicate versus prompt endoscopy for management of dyspeptic patients: a randomised trial
    A T Lassen
    Department of Medical Gastroenterology, Odense University Hospital, Denmark
    Lancet 356:455-60. 2000
    ..We did a randomised trial to assess the efficacy and safety of a test-and-eradicate strategy compared with prompt endoscopy in the management of patients with dyspepsia...
  42. ncbi Clinical trial: long-term use of proton pump inhibitors in primary care patients - a cross sectional analysis of 901 patients
    C Reimer
    Department of Medical Gastroenterology, Køge Hospital, Copenhagen University, Copenhagen, Denmark
    Aliment Pharmacol Ther 30:725-32. 2009
    ..While the incidence of new treatments remains stable, the prevalence of long-term treatment is rising. Studies have shown that up to 70% of patients on chronic acid suppression lack a verified indication for treatment...
  43. ncbi Reproducibility of a symptom response to omeprazole therapy in functional dyspepsia evaluated by a random-starting-day trial design
    L G Madsen
    Department of Medical Gastroenterology, Glostrup University Hospital, Glostrup, Denmark
    Aliment Pharmacol Ther 20:365-72. 2004
    ..Lack of symptom stability impairs the value of the random-starting-day trial and only patients with frequent and stable symptoms should be evaluated in this design...
  44. ncbi Perceptions and beliefs concerning gastroesophageal reflux disease: physicians and patients disagree
    Christina Reimer
    Department of Medical Gastroenterology, Køge University Hospital, Køge, Denmark
    Digestion 76:229-34. 2007
    ..We aimed at investigating physicians' perceptions about GERD and lifestyle and at evaluating physician-patient agreement concerning the impact of GERD on the quality of life...
  45. ncbi [Treatment of hospitalized patients in a medical department with acid-suppressing medication]
    Annika Berntsen
    Amtssygehuset i Glostrup, Medicinsk Afdeling M, Gastroenterologisk Sektion
    Ugeskr Laeger 166:3294-7. 2004
  46. ncbi Discontinuation of long-term proton pump inhibitor therapy in primary care patients: a randomized placebo-controlled trial in patients with symptom relapse
    Christina Reimer
    Department of Medical Gastroenterology, Køge Hospital, Copenhagen University, Køge, Denmark
    Eur J Gastroenterol Hepatol 22:1182-8. 2010
    ..It is possible that a subgroup of empirically treated patients redeem repeated prescriptions because of a positive response to therapy despite symptoms that are not acid related...
  47. ncbi What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment?
    Peter Bytzer
    Department of Medical Gastroenterology, Køge University Hospital, University of Copenhagen, Copenhagen, Denmark
    Clin Gastroenterol Hepatol 7:816-22. 2009
    ..This article reviews the possible reasons why patients are dissatisfied with the way their disease is managed...
  48. ncbi Hepatic transit time of ultrasound contrast in biopsy characterized liver disease
    J F Pedersen
    Department of Radiology, Glostrup Hospital, University of Copenhagen, Denmark
    Acta Radiol 46:557-60. 2005
    ..To study the hepatic transit time of an ultrasound contrast agent in patients with liver disease, and to evaluate the mechanism(s) of the well-established shorter cubital vein to hepatic vein transit time in cirrhosis...
  49. ncbi Review article: Single subject trials as a research instrument in gastrointestinal pharmacology
    L G Madsen
    Department of Medical Gastroenterology M, Glostrup University Hospital, DK-2600 Glostrup, Denmark
    Aliment Pharmacol Ther 16:189-96. 2002
    ..However, the lack of validation and reliability studies limits the value of the single subject trials presented so far...
  50. ncbi Clinical trial guidelines for pharmacological treatment of irritable bowel syndrome
    E Corazziari
    Universita La Sapienza, Rome, Italy Glostrup University Hospital, Copenhagen, Denmark
    Aliment Pharmacol Ther 18:569-80. 2003
    ..h) A 50% improvement in the primary efficacy end-point seems to be a reasonable definition of a responder...
  51. ncbi Information bias in endoscopic assessment
    Peter Bytzer
    Department of Medical Gastroenterology, Glostrup University Hospital, Copenhagen, Denmark
    Am J Gastroenterol 102:1585-7. 2007
    ..Endoscopic assessment is observer dependent and patient history may influence the interpretation of images. This study assessed the impact of knowledge bias in a large sample of endoscopists...
  52. ncbi [Endoscopy in patients receiving anticoagulation or antiplatelet therapy]
    Jens Kjeldsen
    Endoskopiudvalget under Dansk Gastroenterologisk Selskab Odense Universitetshospital, Medicinsk Gastroenterologisk Afdeling S og Kirurgisk Afdeling A, Køge Sygehus, DK 4600 Køge
    Ugeskr Laeger 171:1384-6. 2009
    ..Based on expert opinion and on data from observational studies, we suggest algorithms for the approach to acute and elective procedures based on procedural risk and on risks for thromboembolic episodes...
  53. ncbi On-demand therapy for gastroesophageal reflux disease
    David C Metz
    University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Am J Gastroenterol 102:642-53. 2007
    ..On-demand therapy should not be considered for patients with severe esophagitis...
  54. ncbi [Dyspepsia and Helicobacter--from evidence to clinical practice]
    Peter Bytzer
    Ugeskr Laeger 167:4631. 2005
  55. ncbi Management of the dyspeptic patient: anything goes?
    Peter Bytzer
    Am J Gastroenterol 101:1209-10. 2006
    ..Helicobacter pylori testing is still recommendable owing to the long-term benefits, but the rapidly decreasing Helicobacter prevalence will soon make the test-and-treat strategy cost-ineffective as the initial step...
  56. ncbi Gastro-oesophageal reflux disease: epidemiologic challenges
    Peter Bytzer
    Scand J Gastroenterol 40:247-9. 2005
  57. ncbi Modelling a population with Barrett's oesophagus from oesophageal adenocarcinoma incidence data
    Mark van Blankenstein
    Department of Gastroenterology and Hepatology, Erasmus University Medical Centre, Rotterdam, The Netherlands
    Scand J Gastroenterol 42:308-17. 2007
    ..The aim of this study was to create models estimating the BO population fitting each of these three hypotheses, in order to select the most plausible hypothesis and to gain insight into the Danish BO population...
  58. ncbi [Proton pump inhibitors--are they really harmless?2]
    Peter Bytzer
    Ugeskr Laeger 165:3838-9; author reply 3839. 2003
  59. ncbi Economic analysis of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive reflux disease
    Dyfrig A Hughes
    Centre for the Economics of Health, IMSCaR, University of Wales, Bangor, UK
    Pharmacoeconomics 23:1031-41. 2005
    ..To evaluate the costs and effectiveness of on-demand maintenance therapy with oral esomeprazole, lansoprazole, omeprazole, pantoprazole or rabeprazole in patients with endoscopy-confirmed non-erosive reflux disease (NERD) in the UK...
  60. ncbi [Appropriateness of colonoscopy. Are European standards applicable to a Danish population?]
    Jane Møller Hansen
    Amtssygehuset i Glostrup, Medicinsk Afdeling M
    Ugeskr Laeger 167:1738-42. 2005
  61. ncbi Symptom clustering in subjects with and without diabetes mellitus: a population-based study of 15,000 Australian adults
    Johann Hammer
    , , Vienna, Austria
    Am J Gastroenterol 98:391-8. 2003
    ..12) and Upper GI/Dysmotility cluster (OR = 10.12) when used in combination with insulin. CONCLUSION: Diabetes can be grouped according to common GI symptoms. Glycemic control and treatment for DM predict membership of symptom clusters...
  62. ncbi [The quality of colonoscopy in Denmark. Results from a European quality study]
    Palle Nordblad Schmidt
    H:S Hvidovre Hospital, Gastroenheden
    Ugeskr Laeger 167:1733-7. 2005
  63. ncbi The incidence of adenocarcinoma and squamous cell carcinoma of the esophagus: Barrett's esophagus makes a difference
    Mark van Blankenstein
    Department of Gastroenterology and Hepatology, Erasmus M.C, Rotterdam, The Netherlands
    Am J Gastroenterol 100:766-74. 2005
    ....